JP2022553841A5 - - Google Patents

Info

Publication number
JP2022553841A5
JP2022553841A5 JP2022525957A JP2022525957A JP2022553841A5 JP 2022553841 A5 JP2022553841 A5 JP 2022553841A5 JP 2022525957 A JP2022525957 A JP 2022525957A JP 2022525957 A JP2022525957 A JP 2022525957A JP 2022553841 A5 JP2022553841 A5 JP 2022553841A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553841A (ja
JP7635228B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059210 external-priority patent/WO2021092246A1/en
Publication of JP2022553841A publication Critical patent/JP2022553841A/ja
Publication of JP2022553841A5 publication Critical patent/JP2022553841A5/ja
Application granted granted Critical
Publication of JP7635228B2 publication Critical patent/JP7635228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525957A 2019-11-08 2020-11-05 Tyk2偽キナーゼリガンド Active JP7635228B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933179P 2019-11-08 2019-11-08
US62/933,179 2019-11-08
US202063046514P 2020-06-30 2020-06-30
US63/046,514 2020-06-30
PCT/US2020/059210 WO2021092246A1 (en) 2019-11-08 2020-11-05 Tyk2 pseudokinase ligands

Publications (3)

Publication Number Publication Date
JP2022553841A JP2022553841A (ja) 2022-12-26
JP2022553841A5 true JP2022553841A5 (enExample) 2023-11-13
JP7635228B2 JP7635228B2 (ja) 2025-02-25

Family

ID=75846491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525957A Active JP7635228B2 (ja) 2019-11-08 2020-11-05 Tyk2偽キナーゼリガンド

Country Status (17)

Country Link
US (2) US11753411B2 (enExample)
EP (1) EP4054581A4 (enExample)
JP (1) JP7635228B2 (enExample)
KR (1) KR102938141B1 (enExample)
CN (1) CN114929226B (enExample)
AU (1) AU2020378345A1 (enExample)
BR (1) BR112022008821A2 (enExample)
CA (1) CA3160637A1 (enExample)
CL (1) CL2022001178A1 (enExample)
CO (1) CO2022007814A2 (enExample)
GE (1) GEP20257840B (enExample)
IL (1) IL292785B2 (enExample)
MX (1) MX2022005563A (enExample)
PH (1) PH12022551105A1 (enExample)
TW (1) TWI882032B (enExample)
UA (1) UA129894C2 (enExample)
WO (1) WO2021092246A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
JP2022519696A (ja) * 2019-02-07 2022-03-24 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド
CA3132632A1 (en) * 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
CA3134814A1 (en) 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP7635228B2 (ja) 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2024011136A1 (en) * 2022-07-06 2024-01-11 Ventyx Biosciences, Inc. Crystalline forms of a tyk2 inhibitor
WO2024151992A1 (en) * 2023-01-13 2024-07-18 Ventyx Biosciences, Inc. Preparation of a tyk2 inhibitor
CN117247389A (zh) * 2023-09-18 2023-12-19 南京友怡医药科技有限公司 一种靶向药物化合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7557110B2 (en) 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
PT3371190T (pt) 2015-11-06 2022-07-08 Incyte Corp Compostos heterocíclicos como inibidores de pi3k-gamma
KR102477063B1 (ko) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
TW202515876A (zh) 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018213365A1 (en) 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
SI3658557T1 (sl) * 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
JP7179161B2 (ja) 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ[1,5-a]ピリミジン-3-カルボキサミド誘導体
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
JP2022519696A (ja) 2019-02-07 2022-03-24 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド
CA3132632A1 (en) 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
CA3134814A1 (en) 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP7635228B2 (ja) 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド

Similar Documents

Publication Publication Date Title
JP2022553841A5 (enExample)
JP2022519696A5 (enExample)
JP2022529311A5 (enExample)
JP2024520481A5 (enExample)
JP2023515618A5 (enExample)
JP2021523200A5 (enExample)
IL292785B2 (en) Tyk2 pseudokinase ligands
JP2021522262A5 (enExample)
JP2021523221A5 (enExample)
RU2015108898A (ru) 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ
JP2022545633A5 (enExample)
JP2018504437A5 (enExample)
JP2023520925A5 (enExample)
JP2017504576A5 (enExample)
HRP20161308T1 (hr) 5-alkinil-pirimidini
JP2019531279A5 (enExample)
RU2010143857A (ru) Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина
JP2013525448A5 (enExample)
CA2797533A1 (en) Compounds that modulate intracellular calcium
RU2012142550A (ru) Производные пирролопиразина и их применение в качестве ингибиторов jak и syk
JP2022532877A5 (enExample)
JP2022509206A5 (enExample)
CN109790158A (zh) 作为jak抑制剂杂环化合物,该化合物的盐类及其治疗用途
JP2019535813A5 (enExample)
JP2021528405A5 (enExample)